ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3
www.patentreply.ai/tools/patent-expiration/US11357778Important: This calculator does not include patent term extension under 35 U.S.C. § 156, which may apply to certain drug, biologic, animal drug, and medical device patents.
Learn more about PTE and patent expirationAntagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders Linked With Abnormal Activation Of Fgfr3
Application No. 16662126
December 12, 2032
6y 177d remainingEarliest effective filing
Dec 12, 2012
+ 20 years
Dec 12, 2032
PTA +0d
Dec 12, 2032
TD cap (US 9931341)
Dec 12, 2032
Final
Dec 12, 2032
Filing Date
October 24, 2019
Earliest Effective Filing
December 12, 2012
Issue Date
June 14, 2022
PTA
0 days
Base Expiry (before PTA)
December 12, 2032
Display Device And Display Device Driving Method
Filing Date
Sep 3, 2021
Earliest Effective Filing
Sep 3, 2021
Issue Date
Sep 20, 2022
PTA
0 days
Calculated Expiration
Sep 3, 2041
Antagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders Linked With Abnormal Activation Of Fgfr3
Filing Date
Sep 3, 2015
Earliest Effective Filing
Dec 12, 2012
Issue Date
Apr 3, 2018
PTA
0 days
Calculated Expiration
Dec 12, 2032
Antagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders Linked With Abnormal Activation Of Fgfr3
Filing Date
Oct 24, 2019
Earliest Effective Filing
Dec 12, 2012
Issue Date
Jun 14, 2022
PTA
0 days
Calculated Expiration
Dec 12, 2032
Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.